07.06.2023 - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a .
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta's
WATERTOWN, Mass. (BUSINESS WIRE) Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s internal development program portfolio for hepatitis B virus (HBV) and its.